Why the study?
Early identification of pathogenic mechanisms is essential to predict cardiomyopathy incidence and progression, prompting the exploration of network medicine and artificial intelligence tools for improved diagnosis, prognosis, and precision medicine.
Network medicine and artificial intelligence offer promising holistic approaches for precision medicine, improved phenotyping, and outcome prediction in cardiomyopathies.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for ML integration in cardiomyopathies; leaves open prospective validation before clinical use.
The early identification of pathogenic mechanisms is essential to predict the incidence and progression of cardiomyopathies and to plan appropriate preventive interventions. Noninvasive cardiac imaging such as cardiac computed tomography, cardiac magnetic resonance, and nuclear imaging plays an important role in diagnosis and management of cardiomyopathies and provides useful prognostic information. Most molecular factors exert their functions by interacting with other cellular components, thus many diseases reflect perturbations of intracellular networks. Indeed, complex diseases and traits such as cardiomyopathies are caused by perturbations of biological networks. The network medicine approach, by integrating systems biology, aims to identify pathological interacting genes and proteins, revolutionizing the way to know cardiomyopathies and shifting the understanding of their pathogenic phenomena from a reductionist to a holistic approach. In addition, artificial intelligence tools, applied to morphological and functional imaging, could allow imaging scans to be automatically analyzed to extract new parameters and features for cardiomyopathy evaluation. The aim of this review is to discuss the tools of network medicine in cardiomyopathies that could reveal new candidate genes and artificial intelligence imaging-based features with the aim to translate into clinical practice as diagnostic, prognostic, and predictive biomarkers and shed new light on the clinical setting of cardiomyopathies. The integration and elaboration of clinical habits, molecular big data, and imaging into machine learning models could provide better disease phenotyping, outcome prediction, and novel drug targets, thus opening a new scenario for the implementation of precision medicine for cardiomyopathies.
No takes yet. Share an insight, caveat, or question.
Infante et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: